Hu antigen R and tristetraprolin: Counter‐regulators of rat apical sodium‐dependent bile acid transporter by way of effects on messenger RNA stability
Frank Chen, Ann‐Bin Shyu, Benjamin L. Shneider – 17 June 2011
Tumor‐secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts
Antonio Mazzocca, Francesco Dituri, Luigi Lupo, Michele Quaranta, Salvatore Antonaci, Gianluigi Giannelli – 14 June 2011 – Hepatocellular carcinoma (HCC) occurs in fibrotic liver as a consequence of underlying cirrhosis. The goal of this study was to investigate how the interaction between HCC cells and stromal fibroblasts affects tumor progression. We isolated and characterized carcinoma‐associated fibroblasts (CAFs) and paired peritumoral tissue fibroblasts (PTFs) from 10 different patients with HCC and performed coculture experiments.
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug‐induced liver injury
Ayako Suzuki, Elizabeth M. Brunt, David E. Kleiner, Rosa Miquel, Thomas C. Smyrk, Raul J. Andrade, M. Isabel Lucena, Agustin Castiella, Keith Lindor, Einar Björnsson – 14 June 2011 – Distinguishing drug‐induced liver injury (DILI) from idiopathic autoimmune hepatitis (AIH) can be challenging. We performed a standardized histologic evaluation to explore potential hallmarks to differentiate AIH versus DILI.
Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis
- Read more about Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis
Romina Lomonaco, Carolina Ortiz‐Lopez, Beverly Orsak, Joan Finch, Amy Webb, Fernando Bril, Christopher Louden, Fermin Tio, Kenneth Cusi – 14 June 2011 – The role of ethnicity in determining disease severity in nonalcoholic steatohepatitis (NASH) remains unclear. We recruited 152 patients with biopsy‐proven NASH, 63% of whom were Hispanic and 37% of whom were Caucasian. Both groups were well matched for age, sex, and total body fat.
Prolonged hepatomegaly in mice that cannot inactivate bacterial endotoxin
Baomei Shao, Richard L. Kitchens, Robert S. Munford, Thomas E. Rogers, Don C. Rockey, Alan W. Varley – 14 June 2011 – Transient hepatomegaly often accompanies acute bacterial infections. Reversible, dose‐dependent hepatomegaly also occurs when animals are given intravenous infusions of bacterial lipopolysaccharide (LPS). We found that recovery from LPS‐induced hepatomegaly requires a host enzyme, acyloxyacyl hydrolase (AOAH), that inactivates LPS.
Interleukin‐22 promotes human hepatocellular carcinoma by activation of STAT3
Runqiu Jiang, Zhongming Tan, Lei Deng, Yun Chen, Yongxiang Xia, Yun Gao, Xuehao Wang, Beicheng Sun – 14 June 2011 – Interleukin‐22 (IL‐22), one of the cytokines secreted by T helper 17 (Th17) cells, was recently reported to be a novel inflammation driver through STAT3 signaling activation. We aimed to investigate the role of IL‐22 expression in hepatocellular carcinoma (HCC). We demonstrated significant up‐regulation of IL‐22 in human HCC tumor infiltrated leukocytes (TILs) compared to peripheral lymphocytes.
Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4‐associated cholangitis from cholangiocarcinoma
Abdul M. Oseini, Roongruedee Chaiteerakij, Abdirashid M. Shire, Amaar Ghazale, Joseph Kaiya, Catherine D. Moser, Ileana Aderca, Teresa A. Mettler, Terry M. Therneau, Lizhi Zhang, Naoki Takahashi, Suresh T. Chari, Lewis R. Roberts – 14 June 2011 – Elevated serum immunoglobulin G4 (sIgG4) is a feature of autoimmune pancreatitis (AIP) and IgG4‐associated cholangitis (IAC); a >2‐fold increase in sIgG4 is considered highly specific for these disorders.
Energy drinks: Another red flag for the liver allograft
Carlos A. Apestegui, Olivier Julliard, Olga Ciccarelli, Dhang Khahn Ho Minh Duc, Jan Lerut – 14 June 2011
Hypoxia‐inducible factor 1 alpha–activated angiopoietin‐like protein 4 contributes to tumor metastasis via vascular cell adhesion molecule‐1/integrin β1 signaling in human hepatocellular carcinoma
Hong Li, Chao Ge, Fangyu Zhao, Mingxia Yan, Chen Hu, Deshui Jia, Hua Tian, Miaoxin Zhu, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Jianren Gu, Hong Tu, Xianghuo He, Ming Yao, Yongzhong Liu, Jinjun Li – 14 June 2011 – Angiopoietin‐like protein 4 (ANGPTL4) plays complex and often contradictory roles in vascular biology and tumor metastasis, but little is known about its function in hepatocellular carcinoma (HCC) metastasis.
Response‐guided peg‐interferon plus ribavirin treatment duration in chronic hepatitis C: Meta‐analyses of randomized, controlled trials and implications for the future
Vincent Di Martino, Carine Richou, Jean‐Paul Cervoni, Jose M. Sanchez‐Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot – 14 June 2011 – Response‐guided pegylated interferon (peg‐IFN) plus ribavirin (P/R) therapy trials on genotype (G)1 and G2/G3 hepatitis C virus–infected patients provide contradictory results. We conducted meta‐analyses of randomized, controlled trials to address (1) the benefit of a 72‐week extended‐duration therapy in G1‐slow responders and (2) adequate shortened duration therapy in G1 and G2/G3‐rapid responders.